Rallybio Halts Development of Lead FNAIT Program Following Phase 2 Failure

Rallybio RLYB212, Fetal and neonatal alloimmune thrombocytopenia (FNAIT), Phase 2 clinical trial, Maternal immune disorder therapy, Biotech pipeline shift